Phase 2 study of intratumoral vidutolimod in combination with intravenous cemiplimab in patients with selected advanced cancer or metastatic cancer: trial in progress

• S. Bhatia,
• D. Davar,
• S. Thomas,
• A.W. Silk,
• R.C. Wu,
• R. Ladwa,
• S.J. Park,
• C.M. Kelly,
• D.J. Wong,
• J. Grewal,
• N. Vohra,
• A.M. Lim,
• J. Puegero,
• C. Verschraegen,
• B. Zhong,
• I. Lowy,
• M. Fury,
• M. Cristea

Affiliations

S. Bhatia

University of Washington and Fred Hutchinson Cancer Center, Medicine, Seattle, WA, United States of America

D. Davar

UPMC, Pittsburgh, PA, United States of America

S. Thomas

Orlando Health Cancer Institute, Orlando, FL, United States of America

A.W. Silk

Dana-Farber Cancer Institute, Boston, MA, United States of America

R.C. Wu

The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States of America

R. Ladwa

Princess Alexandra Hospital, Brisbane, Queensland, Australia

S.J. Park

UC San Diego Moores Cancer Center, La Jolla, CA, United States of America

C.M. Kelly

Memorial Sloan Kettering Cancer Center, New York, NY, United States of America

D.J. Wong

UCLA, Los Angeles, CA, United States of America

J. Grewal

Norton Cancer Institute, Louisville, KY, United States of America

N. Vohra

East Carolina University, Greenville, NC, United States of America

A.M. Lim

The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

J. Puegero

Oncology Consultants, Houston, TX, United States of America

C. Verschraegen

The Ohio State University James Comprehensive Cancer Center, Columbus, OH, United States of America

B. Zhong

Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, United States of America

I. Lowy

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America

M. Fury

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America

M. Cristea

Regeneron Pharmaceuticals, Inc., Duarte, CA, United States of America